Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May;36(5):997-1010.
doi: 10.1007/s12325-019-00920-x. Epub 2019 Mar 16.

The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview

Affiliations
Review

The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview

Marielle G Contesse et al. Adv Ther. 2019 May.

Abstract

Introduction: The traditional model of evaluating treatments based primarily on primary outcome measures has stumbled in its application to rare disease. Rare disease clinical trials face the methodological challenges of small, heterogeneous patient populations and relatively few validated, disease-specific outcome measures. Incorporating qualitative research into rare disease clinical trials may help sponsors, regulators, payers, and prescribers to better understand the real-world and patient-specific impact of a potential therapy. This paper provides a methodologic overview of the use of Patient and Caregiver Perception of Change (PPC and CPC) Assessments utilizing patient and caregiver video interviews to complement the data captured by traditional endpoints in rare disease clinical trials.

Methods: Incorporating qualitative patient and caregiver video interviews into clinical trials allows for the rigorous capture of patient experiences and caregiver observations. Interview guides informed by input from key stakeholders provide the opportunity to solicit structured feedback on experiences before, during, and after the clinical trial. Patients and caregivers can complete their video interviews in a study mobile application, and interview transcripts are analyzed by independent coders. Themes are summarized by the treatment group and individual patient, which adds context to the clinical outcome measures of how patients feel and function, as well as elucidates the degree of change that is meaningful to patients and caregivers. The qualitative results can be compared to the data captured in clinical trials to assess data concordance.

Conclusion: Capturing patient experience data with sufficient rigor allows it to contribute to the body of evidence utilized in regulatory, payer, and prescriber decision-making. Adding PPC and CPC Assessments to rare disease clinical trials offers an innovative and powerful way to tap into the unique insights of patients and their families to develop a fuller picture of the patient experience in the clinical trial.

Funding: Stealth BioTherapeutics Inc.

Keywords: Clinical outcome assessment; Genetic disease; Mixed methods research; Observer-reported outcomes; Patient experience data; Patient focused drug development; Patient-reported outcomes; Qualitative research; Rare diseases.

PubMed Disclaimer

Conflict of interest statement

Tracy E. Wall works for Stealth BioTherapeutics Inc., the funder of this research. Marielle Goyette Contesse works for Casimir, a company that received payment from Stealth BioTherapeutics Inc., for work on this manuscript. Mindy G. Leffler works for Casimir, a company that received payment from Stealth BioTherapeutics Inc., for work on this manuscript. James E. Valentine works for Hyman, Phelps & McNamara, P.C., a law firm that represents Stealth BioTherapeutics Inc., including through the time when work was performed on this manuscript.

Figures

Fig. 1
Fig. 1
Inputs into and impacts from Patient and Caregiver Perception of Change Assessments during a clinical trial
Fig. 2
Fig. 2
Process of conducting the interviews using the secure mobile application

Similar articles

Cited by

References

    1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Rare diseases: common issues in drug development—guidance for industry. Silver Spring, MD; 2019.
    1. Kempf L, Goldsmith JC, Temple R. Challenges of developing and conducting clinical trials in rare disorders. Am J Med Genet A. 2018;176:773–783. doi: 10.1002/ajmg.a.38413. - DOI - PubMed
    1. Slade A, Isa F, Kyte D, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13:61. doi: 10.1186/s13023-018-0810-x. - DOI - PMC - PubMed
    1. NIH. FAQs About Rare Diseases | Genetic and Rare Diseases Information Center (GARD)—an NCATS Program [Internet]. 2017. https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-dise.... Accessed 19 Sept 2018.
    1. RARE Diseases: Facts and statistics [Internet]. Global Genes. 2012. http://globalgenes.org/rare-diseases-facts-statistics/. Accessed 19 Sept 2018.

Publication types

MeSH terms